155 related articles for article (PubMed ID: 15661266)
1. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
Schirrmann T; Pecher G
Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
[TBL] [Abstract][Full Text] [Related]
2. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
3. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
[TBL] [Abstract][Full Text] [Related]
4. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
5. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
6. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells.
Falco M; Marcenaro E; Romeo E; Bellora F; Marras D; Vély F; Ferracci G; Moretta L; Moretta A; Bottino C
Eur J Immunol; 2004 Jun; 34(6):1663-72. PubMed ID: 15162436
[TBL] [Abstract][Full Text] [Related]
7. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
Hernández-Caselles T; Martínez-Esparza M; Pérez-Oliva AB; Quintanilla-Cecconi AM; García-Alonso A; Alvarez-López DM; García-Peñarrubia P
J Leukoc Biol; 2006 Jan; 79(1):46-58. PubMed ID: 16380601
[TBL] [Abstract][Full Text] [Related]
8. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
9. Expression of an anti-CD33 single-chain antibody by Pichia pastoris.
Emberson LM; Trivett AJ; Blower PJ; Nicholls PJ
J Immunol Methods; 2005 Oct; 305(2):135-51. PubMed ID: 16139294
[TBL] [Abstract][Full Text] [Related]
10. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
11. Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.
Chin LT; Chu C; Chen HM; Hsu SC; Weng BC; Chu CH
BMC Biotechnol; 2007 Aug; 7():51. PubMed ID: 17714596
[TBL] [Abstract][Full Text] [Related]
12. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
13. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy.
Gupta N; Arthos J; Khazanie P; Steenbeke TD; Censoplano NM; Chung EA; Cruz CC; Chaikin MA; Daucher M; Kottilil S; Mavilio D; Schuck P; Sun PD; Rabin RL; Radaev S; Van Ryk D; Cicala C; Fauci AS
Virology; 2005 Feb; 332(2):491-7. PubMed ID: 15680414
[TBL] [Abstract][Full Text] [Related]
14. [Construction, expression and functional characterization of single chain variable fragments (scFv) against human CD33 antigen].
Chen XJ; Wang Y; Qu H; Ge XS; Zuo YF; Liao XL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1147-9. PubMed ID: 18062889
[TBL] [Abstract][Full Text] [Related]
15. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
[TBL] [Abstract][Full Text] [Related]
16. Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.
Myers KA; Ryan MG; Stern PL; Shaw DM; Embleton MJ; Kingsman SM; Carroll MW
Cancer Gene Ther; 2002 Nov; 9(11):884-96. PubMed ID: 12386827
[TBL] [Abstract][Full Text] [Related]
17. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.
Germain C; Larbouret C; Cesson V; Donda A; Held W; Mach JP; Pèlegrin A; Robert B
Clin Cancer Res; 2005 Oct; 11(20):7516-22. PubMed ID: 16243826
[TBL] [Abstract][Full Text] [Related]
18. Chimeric and humanized antibodies with specificity for the CD33 antigen.
Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C
J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
J Gastroenterol Hepatol; 2006 Sep; 21(9):1439-47. PubMed ID: 16911690
[TBL] [Abstract][Full Text] [Related]
20. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
